UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 10-Q

(MARK ONE)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2009

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ___________ to __________

Commission file number: 000-32603
 


ARBIOS SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Delaware
91-1955323
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

80 Commerce Drive, Allendale, NJ
07401
(Address of principal executive offices)
(Zip Code)

 (201) 995-1919
(Registrant's telephone number, including area code)

530 S. Lake Avenue, Unit 363, Pasadena, CA 91101
(Former name, former address and former fiscal year, if changed since last report)
______________________________

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    
Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of  “large accelerated filer,”  “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer o
Accelerated filer o
Non-accelerated filer o
(do not check if a smaller reporting company)
Smaller reporting company x

 
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

On September 30, 2009, there were 50,000,000 shares of common stock, $.001 par value per share, issued and outstanding.
 
2


 
ARBIOS SYSTEMS, INC.
FORM 10-Q
TABLE OF CONTENTS

PAGE NO.
PART I. FINANCIAL INFORMATION
 
     
Item 1.
Financial Statements:
 
     
 
Condensed Balance Sheets as of September 30, 2009 (unaudited) and
 
 
December 31, 2008 (audited)
4
     
 
Condensed Statements of Operations for the three and nine months ended
 
September 30, 2009 and 2008 and from August 23, 2000 (inception) through
 
 
September 30, 2009 (unaudited)
5
     
 
Condensed Statements of Cash Flows for the nine months ended
 
 
September 30, 2009 and 2008 and from August 23, 2000 (inception) through
 
 
September 30, 2009 (unaudited)
6
     
 
Condensed Statement of Stockholders’ Equity (Deficit) from August 23, 2000 (inception)
 
 
through September 30, 2009 (unaudited)
7
     
 
Notes to Condensed Financial Statements 
12
     
Item 2.
Management's Discussion and Analysis of Financial Condition and Results
 
 
of Operations
19
     
Item 3.
Qualitative and Quantitative Disclosures About Market Risk...............................
23
     
Item 4T.
Controls and Procedures
23
     
PART II. OTHER INFORMATION
 
     
Item 1.
Legal Proceedings
23
     
Item 1A.
Risk Factors
24
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
24
     
Item 3.
Defaults Upon Senior Securities
 24
     
Item 4.
Submission of Matters to a Vote of Security Holders
24
     
Item 5.
Other Information
24
     
Item 6.
Exhibits
24
     
SIGNATURES
 
25

 
3

 
PART I - FINANCIAL INFORMATION

ITEM 1.  Condensed Financial Statements

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED BALANCE SHEETS
 
             
   
Successor
   
Predecessor
 
   
September 30, 2009
   
December 31,
 
ASSETS
 
(Unaudited)
   
2008
 
             
Current assets
           
Cash
  $ 193,815     $ 370,686  
Cash held in attorney trust
    270,323       -  
Prepaid expenses
    -       21,506  
Total current assets
    464,138       392,192  
                 
Receivable
    -       200,000  
Property and equipment, net
    -       6,177  
Investment
    -       86,209  
Other assets
    -       750  
                 
Total assets
  $ 464,138     $ 685,328  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
               
Current liabilities
               
Accounts payable
  $ 470,870     $ 194,046  
Accrued expenses
    -       286,888  
Total current liabilities
    470,870       480,934  
                 
Long term contract obligations
    -       150,000  
Total liabilities
    470,870       630,934  
                 
Stockholders' equity (deficit)
               
Successor common stock, $.001 par value; 100,000,000 shares authorized; 50,000,000
         
shares issued and outstanding at September 30, 2009
    50,000       -  
Predecessor common stock, $.001 par value; 100,000,000 shares authorized; 25,792,747
         
shares issued and outstanding at December 31, 2008
    -       25,792  
Additional paid-in capital
    143,256       21,617,075  
Receivable for stock issuance
    (199,988 )     -  
Deficit accumulated during the development stage
    -       (21,588,473 )
Total stockholders' equity (deficit)
    (6,732 )     54,394  
                 
Total liabilities and stockholders' equity (deficit)
  $ 464,138     $ 685,328  
 
The accompanying notes are an integral part of these condensed financial statements.


4



ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
 
   
Predecessor
 
Predecessor
 
Predecessor
   
Predecessor
   
Predecessor
 
   
For the three months ended September 30,
 
For the nine months ended September 30,
   
Inception to
 
   
2009
   
2008
   
2009
   
2008
   
September 30, 2009
 
                               
Revenues
  $ -     $ -     $ -     $ -     $ 320,966  
                                         
Operating expenses:
                                       
General and administrative
    256,348       147,103       660,795       1,358,718       13,902,846  
Research and development
    -       164,350       -       1,220,747       9,325,632  
Total operating expenses
    256,348       311,453       660,795       2,579,465       23,228,478  
                                         
Operating loss
    (256,348 )     (311,453 )     (660,795 )     (2,579,465 )     (22,907,512 )
                                         
Other income (expense):
                                       
Loss from disposition of fixed assets
    (3,120 )     -       (3,120 )     -       (3,120 )
Interest income
    -       3,786       229       32,264       497,748  
Gain on sale of HepatAssist program, net
    -       -       404,863  
Loss on investment
    -       -       (86,209 )     -       (86,209 )
Interest expense
    -       -       -       -       (244,138 )
Total other income (expense)
    (3,120 )     3,786       (89,100 )     32,264       569,144  
                                         
Loss before reorganization items, net
    (259,468 )     (307,667 )     (749,895 )     (2,547,201 )     (22,338,368 )
                                         
Reorganization items, net
    147,885       -       (111,243 )     -       (111,243 )
                                         
Net loss
  $ (111,583 )   $ (307,667 )   $ (861,138 )   $ (2,547,201 )   $ (22,449,611 )
                                         
Net loss per share:
                                       
Basic and diluted
  $ (0.00 )   $ (0.01 )   $ (0.03 )   $ (0.10 )        
                                         
Weighted-average shares:
                                       
Basic and diluted
    26,892,442       25,792,747       25,249,003       25,712,950          
 
The accompanying notes are an integral part of these condensed financial statements.


5


ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
 
   
Predecessor
   
Predecessor
   
Predecessor
 
   
For the nine months ended September 30,
   
Inception to
 
   
2009
   
2008
   
September 30, 2009
 
Cash flows from operating activities:
                 
Net loss
  $ (861,138 )   $ (2,547,201 )   $ (22,449,611 )
Adjustments to reconcile net loss to net cash
                       
used in operating activities:
                       
Amortization of debt discount
    -       -       244,795  
Depreciation and amortization
    2,757       32,190       338,794  
Patent rights impairment
    -       -       91,694  
Issuance of common stock, options and warrants for compensation
    -       441,055       4,071,460  
Issuance of warrants for patent acquistion
    -       -       74,570  
Settlement of accrued expense
    -       -       54,401  
Deferred compensation costs
    -       -       319,553  
Loss on disposition of fixed assets
    3,120       2,207       8,157  
Loss on disposition of investment
    86,209       -       86,209  
Gain on sale of HepatAssist program, net
    -       -       (404,863 )
Non-cash reorganization items, net
    (226,103 )     -       (226,103 )
Changes in operating assets and liabilities:
                       
Prepaid expenses
    21,506       35,459       -  
Deferred financing costs
    -       16,757       -  
Other assets
    750       68,686       -  
Accounts payable
    322,927       (114,149 )     516,971  
Accrued expenses
    (106,888 )     (97,367 )     86,498  
Other liabilities
    -       -       64,695  
Contract obligations
    (150,000 )     (100,000 )     -  
Net cash used in operating activities
    (906,860 )     (2,262,363 )     (17,122,780 )
                         
Cash flows from investing activities:
                       
Additions of property and equipment
    -       -       (149,467 )
Proceeds from sale of fixed assets
    300       4,175       4,476  
Proceeds from sale of HepatAssist program
    200,000       -       450,000  
Purchase of short term investments
    -       -       (21,866,787 )
Maturities of short term investments
    -       -       21,866,787  
Net cash provided from investing activities
    200,300       4,175       305,009  
                         
Cash flows from financing activities:
                       
Proceeds from issuance of convertible debt
    -       -       400,000  
Proceeds from common stock option/warrant exercise
    -       -       67,900  
Net proceeds from issuance of common stock and warrants
    800,012       -       16,597,092  
Net proceeds from issuance of preferred stock
    -       -       238,732  
Payments on capital lease obligation, net
    -       -       (21,815 )
Net cash provided by financing activities
    800,012       -       17,281,909  
Net (decrease) increase in cash
    93,452       (2,258,188 )     464,138  
                         
Cash at beginning of period
    370,686       2,735,944       -  
                         
Cash at end of period
  $ 464,138     $ 477,756     $ 464,138  
                         
Supplemental disclosures of non-cash financing activity
                       
Issuance of securities for obligation related to finder's fees
  $ -     $ -     $ 47,500  
 
The accompanying notes are an integral part of these condensed financial statements.
 
6


ARBIOS SYSTEMS,  INC.
(A Development Stage Company)
 CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)
 
                                             
Deficit
       
                                             
Accumulated
       
                           
Additional
   
Receivable
         
During the
       
   
Preferred Stock
   
Common Stock
   
Paid-In
   
for Stock
   
Deferred
   
Development
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Issuance
   
Costs
   
Stage
   
Total
 
                                                       
Balance, August 23,
                                                     
2000 (inception) restated
    -     $ -       -     $ -     $ -     $ -     $ -     $ -     $ -  
for effect of reverse merger
with Historical Autographs U.S.A. Inc.
                                                                       
                                                                         
Stock issuance
                                                                       
in exchange for cash
                    5,000,000       50       4,950                               5,000  
                                                                         
Net loss
                                                            (9,454 )     (9,454 )
                                                                         
Balance, December 31,
                                                                       
2000, as restated
    -       -       5,000,000       50       4,950       -       -       (9,454 )     (4,454 )
                                                                         
Issuance of junior preferred stock
                                                                       
for cash of $250,000 and in
                                                                       
exchange for $400,000 in patent rights,
                                                                       
research and development costs,
                                                                       
and employee loanout costs less
                                                                       
issuance expenses
                                                                       
of $11,268, June 29, 2001
    681,818       7                       958,278               (343,553 )             614,732  
                                                                         
Issuance of common stock in exchange
                                                                       
for patent rights and deferred research
                                                                       
and development costs
                    362,669       4       547,284                               547,288  
                                                                         
Services receivable
                                                    (550,000 )             (550,000 )
                                                                         
Deferred employee
                                                                       
loan-out costs
                                                                       
receivable earned
                                                    82,888               82,888  
                                                                         
Net loss
                                                            (237,574 )     (237,574 )
                                                                         
Balance, December 31, 2001
    681,818       7       5,362,669       54       1,510,512       -       (810,665 )     (247,028 )     452,880  
                                                                         
 
The accompanying notes are an integral part of these condensed financial statements.
 
7

 
ARBIOS SYSTEMS,  INC.
(A Development Stage Company)
 CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)
 
                                             
Deficit
       
                                             
Accumulated
       
                           
Additional
   
Receivable
         
During the
       
   
Preferred Stock
   
Common Stock
   
Paid-In
   
for Stock
   
Deferred
   
Development
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Issuance
   
Costs
   
Stage
   
Total
 
                                                       
Amendment of December 31, 2001
                                                     
agreement for the issuance of
                                                     
common stock agreement in
                                                     
exchange for research and
                                                     
development services
                            (495,599 )           550,000             54,401  
                                                             
Deferred employee loan out
                                                           
costs receivable earned
                                          171,776             171,776  
                                                             
Issuance of common
                                                           
stock for compensation
                70,000       1       10,499                           10,500  
                                                                 
Issuance of common stock for cash
                999,111       9       149,857                           149,866  
                                                                 
Net loss
                                                      (494,780 )     (494,780 )
                                                                   
Balance, December  31, 2002
    681,818       7       6,431,780       64       1,175,269       -       (88,889 )     (741,808 )     344,643  
                                                                         
Issuance of common stock for cash
                                                                       
less issuance expense of $2,956
                    417,000       417       246,827                               247,244  
                                                                         
Issuance of common stock in private
                                                                       
placement for cash less
                                                                       
issuance expense of $519,230
                    4,000,000       4,000       3,476,770                               3,480,770  
                                                                         
Issuance of common stock
                                                                       
for convertible debenture less
                                                                       
issuance expense of $49,500
                    400,000       400       350,100                               350,500  
                                                                         
Shares issued in connection with
                                                                       
acquisition of Historical Autographs
                                                                       
U.S.A., Inc. on October 30, 2003
                    1,220,000       8,263       (8,263 )                             -  
 
The accompanying notes are an integral part of these condensed financial statements.
 
8

 
ARBIOS SYSTEMS,  INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)
 
                                             
Deficit
       
                                             
Accumulated
       
                           
Additional
   
Receivable
         
During the
       
   
Preferred Stock
   
Common Stock
   
Paid-In
   
for Stock
   
Deferred
   
Development
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Issuance
   
Costs
   
Stage
   
Total
 
                                                       
Value of warrants and beneficial
                                                     
conversion feature of bridge loan
                            244,795                         244,795  
                                                           
Deferred employee loan-out